British Cannabis (CBD Health Foods Ltd) is celebrating after 310 of its CBD products have now passed onto the crucial next stage of the UK Novel Foods process for CBD food supplements.
British Cannabis now has a 9 per cent share of the UK market. With a total of 3,536 products featuring on the Food Standards Agency’s (FSA) CBD, the 310 British Cannabis products gives the company the highest number of products permitted for general sale of any brand or manufacturer.
It featured products include five of the company’s own-brand portfolio, from the CBD by BRITISH CANNABIS, Access CBD and CBD Health ranges. Also progressing on towards the ‘validation stage’ are 235 individual products across several leading brands ‘Powered by BRITISH CANNABIS’ under the company’s white label manufacturing services.
British Cannabis CEO, Thomas Whettem, commented: “This is a monumental moment for our company and a recognition of three years of work and investment from myself and our dedicated project team.
“Our aim from the start in 2015 has been to act as an authority when it comes to CBD products that people can trust. Now, having cornered the market with nearly 1-in-10 of the CBD products remaining legal to sell in the UK, I am galvanised that we are on our way to achieving this goal.
Read more: British Cannabis CBD products to list on eBay
“We had 15 individual Novel Foods dossier submissions to the FSA, spanning thousands of pages and many hours of providing evidence. This gave us a substantial 20 per cent of all of the RP numbers appearing on this public list today.
“The evidence gathered included our thorough testing, product safety and purity, and our passion for compliant products that do and contain what we say they do. It’s our vision that retailers and consumers alike will be able to continue to place their trust in British Cannabis for many years to come.”
British Cannabis managing director, David Ralson, added: “I can hardly put into words how excited and proud this announcement makes me, both for my team and for all of the customers that support our products. To be confirmed at this time as the most predominate manufacturer in the UK for the number of products on the FSA public list is gratifying for all of the dedication we have put into doing things the best way possible and in order to make our products sustainable for the future.
“Our partners at the Association for The Cannabinoid Industry (ACI) have been supporting us in progressive communication along the way with both the FSA and Trading Standards. As soon as the consortium toxicology study that we have partaken in with the ACI and its members is ready for release, we look forward to our products currently listed as ‘Awaiting Evidence’ on the public list to move on to ‘Validated’ status, and then to full approval in the next year or two.
“I would encourage all of our customers and consumers, existing and future, to check the FSA public list carefully; is your CBD supplement on the list? If not, why? Our Primary Partnership with Berkshire and Buckinghamshire Trading Standards sees us ready to advise retailers who have questions about this process and what compliant CBD products they should be stocking.
“We are delighted to be able to offer them a greater choice of compliant cannabis food products moving forward than any other manufacturer.”
The company highlights that its products are among the few remaining on the market to use ‘100 per cent cannabis”, naturally derived formulas in their CBD oils. This means the products contain the hundreds of clinically proven plant phytochemicals found in cannabis, whilst also being 0 per cent THC. Their food supplements are also free from other restricted cannabinoids.
[activecampaign form=31]
